Jonathan Violin - Net Worth and Insider Trading

Jonathan Violin Net Worth

The estimated net worth of Jonathan Violin is at least $6 Million dollars as of 2024-05-14. Jonathan Violin is the Chief Executive Officer of Viridian Therapeutics Inc and owns about 430,905 shares of Viridian Therapeutics Inc (VRDN) stock worth over $6 Million. Details can be seen in Jonathan Violin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jonathan Violin has not made any transactions after 2023-02-02 and currently still holds the listed stock(s).

Transaction Summary of Jonathan Violin

To

Jonathan Violin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jonathan Violin owns 4 companies in total, including Trevena Inc (TRVN) , Astria Therapeutics Inc (ATXS) , and Viridian Therapeutics Inc (VRDN) among others .

Click here to see the complete history of Jonathan Violin’s form 4 insider trades.

Insider Ownership Summary of Jonathan Violin

Ticker Comapny Transaction Date Type of Owner
TRVN Trevena Inc 2018-01-29 SVP-Scientific Affairs & IR
ATXS Astria Therapeutics Inc 2021-01-28 director
VRDN Viridian Therapeutics Inc 2023-02-02 President and COO
2023-09-11 director

Jonathan Violin Latest Holdings Summary

Jonathan Violin currently owns a total of 1 stock. Jonathan Violin owns 430,905 shares of Viridian Therapeutics Inc (VRDN) as of February 2, 2023, with a value of $6 Million.

Latest Holdings of Jonathan Violin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VRDN Viridian Therapeutics Inc 2023-02-02 430,905 14.34 6,179,178

Holding Weightings of Jonathan Violin


Jonathan Violin Form 4 Trading Tracker

According to the SEC Form 4 filings, Jonathan Violin has made a total of 6 transactions in Viridian Therapeutics Inc (VRDN) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Viridian Therapeutics Inc is the sale of 50,000 shares on February 2, 2023, which brought Jonathan Violin around $2 Million.

Insider Trading History of Jonathan Violin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jonathan Violin Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jonathan Violin Ownership Network

Ownership Network List of Jonathan Violin

No Data

Ownership Network Relation of Jonathan Violin


Jonathan Violin Owned Company Details

What does Trevena Inc do?

Who are the key executives at Trevena Inc?

Jonathan Violin is the SVP-Scientific Affairs & IR of Trevena Inc. Other key executives at Trevena Inc include SVP & Chief Medical Officer Mark Demitrack , SVP & Chief Business Officer Robert T Yoder , and director & President & CEO Carrie L. Bourdow .

Trevena Inc (TRVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Trevena Inc (TRVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Trevena Inc (TRVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Trevena Inc (TRVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Trevena Inc Insider Transactions

No Available Data

Jonathan Violin Mailing Address

Above is the net worth, insider trading, and ownership report for Jonathan Violin. You might contact Jonathan Violin via mailing address: 955 Chesterbrook Boulevard, Suite 200, Chesterbrook Pa 19087.

Discussions on Jonathan Violin

No discussions yet.